Marti Technologies shares fall 2.34% after-hours as Phase 3 SELVA trial enrollment completed.

Marti Technologies Inc. declined 2.34% in after-hours trading. The company announced that its Phase 3 SELVA trial evaluating QTORIN™ rapamycin for microcystic lymphatic malformations has completed enrollment, exceeding the target by over 25%, with top-line results expected in the first quarter of 2026. Additionally, top-line results for the Phase 2 TOIVA trial evaluating QTORIN™ rapamycin for cutaneous venous malformations are on track for the fourth quarter of 2025. The company also plans to announce a third clinical indication for QTORIN™ rapamycin and a second QTORIN™ platform candidate before year-end 2025.